# A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Study · id `cardio:ct-nct07668388` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07668388](<https://clinicaltrials.gov/study/NCT07668388>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07668388

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07668388. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-22 (actual); primary completion 2027-10-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07668388, source copy `cardio:ctgov-nct07668388-2026-10-07`, retrieved 2026-10-26)
- Started: 2026-06-22 (actual) (ClinicalTrials.gov record NCT07668388, source copy `cardio:ctgov-nct07668388-2026-10-07`, retrieved 2026-10-26)
- Primary completion: 2027-10-04 (anticipated) (ClinicalTrials.gov record NCT07668388, source copy `cardio:ctgov-nct07668388-2026-10-07`, retrieved 2026-10-26)
- Completion: 2027-11-15 (anticipated) (ClinicalTrials.gov record NCT07668388, source copy `cardio:ctgov-nct07668388-2026-10-07`, retrieved 2026-10-26)
- Countries: United States; Australia; Germany; Hungary; Poland; Romania; Slovakia; South Korea; Spain (ClinicalTrials.gov record NCT07668388, source copy `cardio:ctgov-nct07668388-2026-10-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07668388-2026-10-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): UBT251
- Intervention (Drug): UBT251 Placebo
- Intervention (Drug): Semaglutide
- Intervention (Drug): Semaglutide Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 1641e104f412232ee3e855417de4923efe95ededac775d3776c20f646e910009
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
